X

ASCPT Awards

Each year ASCPT's Awards program provides an array of awards that recognize outstanding science and achievement in clinical pharmacology and translational science. ASCPT's awards span the continuum of clinical pharmacology, translational medicine, and therapeutics. The array of awards is designed to recognize every turning point in the career path from young investigator to seasoned scientist with the focus on exceptional achievements in the dimensions that the awards are focused.  

Please click here to see the 2018 Awards Recipients.

The Gary Neil Prize for Innovation in Drug Development was established in 2004 to honor the memory of Gary Neil, PhD. Dr. Neil, a former leader of worldwide Research and Development at Wyeth-Ayerst, was a pioneer in the field of drug development. Dr. Neil was instrumental in creating a highly effective drug development and strategic decision-making structure at Alza through his roles as CEO and President of Therapeutic Discovery Corporation and Crescendo Pharmaceuticals Corporation. Dr. Neil had a significant role as a member of the boards of directors of Pharsight Corporation, Geron Corporation, Calydon and several other biotech companies. 

The goal of the Gary Neil Prize for Innovation in Drug Development is to stimulate the application of innovative science to clinical drug development by recognizing outstanding individuals or teams who have been leaders in this area. 

Eligibility 
Individuals as well as teams who have demonstrated leadership in the application of significant, innovative science to clinical drug development. The award is open to individuals from all clinical pharmacology employment sectors. 

Prize and Presentation 
The Gary Neil Prize for Innovation in Drug Development will be presented at the ASCPT Annual Meeting. The recipient will receive a plaque and a $2,500 prize. Travel expenses, hotel expenses, and meeting registration will be reimbursed by the Society. 

The Leon I. Goldberg Early Investigator Award was established in 1986 to honor a young scientist for accomplishments in the field of clinical pharmacology achieved early in his/her career. 

The goal of the Leon I. Goldberg Early Investigator Award is to encourage and recognize these scientists active in the field of clinical pharmacology. 

Eligibility 
The nominee can be an academic, industrial, or regulatory scientist who has made a substantial contribution to clinical pharmacology within 10 years of the completion of an advanced degree and/or a post-doctoral fellowship or residency program. An important aspect is that the recipient will be able to deliver an engaging presentation about the impact of their research. The award is intended to foster the candidate’s potential for significant contributions to the future of clinical pharmacology.

The nominator’s assessment and letters of recommendation should contain evidence that the candidate has documented scientific contributions, as evidenced by either well cited publications, grants, patents, independent influence on important drug development or regulatory decisions, or other recognitions as may be relevant.

There are no restrictions concerning the scientific field in which nominees have earned their doctoral degrees. Although it is encouraged, a nominee need not be a member of the Society.  

Prize and Presentation 
The Leon I. Goldberg Early Investigator Award is presented at the ASCPT Annual Meeting. The recipient will deliver a lecture on his/her work. In addition, the recipient of the award will receive a plaque and a $1,000 prize. Travel expenses, hotel expenses, and meeting registration are reimbursed by the Society. 

The Oscar B. Hunter Career Award in Therapeutics was established in 1955 to honor individual scientists for outstanding contributions to clinical pharmacology and therapeutics. This award recognizes a meritorious career in drug research, excellence or contributions in direct patient care, and a distinguished teaching career. The Oscar B. Hunter Career Award in Therapeutics is the Society's premier award. The goal of the award is to honor a scientist for outstanding contributions to clinical pharmacology and therapeutics over the individual's professional life. 

Eligibility 
The nominee can be an academic, industrial, or regulatory scientist who has demonstrated a sustained record of lifelong contributions to clinical pharmacology and dissemination of knowledge who will be able to give an engaging presentation about their career and the impact of their work.  

The nominator’s assessment and letters of recommendation should provide evidence of the nominee’s exemplary career as a leader, including sufficient documented scientific contributions, as evidenced by either high impact publications, patents, independent influence on important drug discovery, drug development or regulatory decisions, or other recognitions as may be relevant. Particular emphasis should be provided on the lifetime contributions of this nominee and the impact of their accomplishment to clinical pharmacology.

The nominee must be a well-recognized leader in clinical pharmacology, but does not need to be an ASCPT member.

Prize and Presentation 
The Oscar B. Hunter Career Award in Therapeutics is presented at the ASCPT Annual Meeting. The recipient will present a lecture summarizing the works that form the basis of the award. In addition, the recipient of the award will receive a bronze medal mounted on a plaque and a $1,500 prize. Travel expenses, hotel expenses, and meeting registration will be reimbursed by the Society.

The Rawls-Palmer Progress in Medicine Award was established in 1978 by Dr. W. B. Rawls to further his commitment to continuing medical education and its impact on patient care. This award was founded through the generosity of the late Dr. and Mrs. W.B. Rawls, and honors the memory of their parents. 

The goal of the Rawls-Palmer Progress in Medicine Award is to incorporate the efforts of modern research in patient care and to help bridge the gap between the results of research and its application in patient care. 

Eligibility 
A nominee can be an academic, industrial, or regulatory scientist who is widely recognized for their transformational and/or translational discoveries or innovative approaches impacting clinical pharmacology research and clinical practice.

The nominator’s assessment and letter(s) of recommendation should provide evidence of the nominee’s exemplary record, including sufficient documented scientific contributions from research that lead to direct applications in patient care, as evidenced by either well cited publications, patents, independent influence on important drug development or regulatory decisions, or other recognitions (as may be relevant).

A nominee does not need to be an ASCPT member.

Prize and Presentation 
The Rawls-Palmer Progress in Medicine Award is presented at the ASCPT Annual Meeting. The recipient will present a lecture focusing on recent developments in clinical pharmacology. In addition, the recipient will receive a $1,000 prize and a plaque. Travel expenses, hotel expenses, and meeting registration will be reimbursed by the Society. 

The Sheiner-Beal Pharmacometrics Award has been established as an ASCPT Award by the Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco (UCSF) to acknowledge the pioneering contributions of Drs. Lewis B. Sheiner and Stuart Beal to the scientific discipline of pharmacometrics. 

Pharmacometrics is defined as the science that quantifies drug, disease and clinical trial information to aid efficient drug development, regulatory decisions, and rational therapeutic decision making in patients. It uses models that are generally based on pharmacology, physiology, genetic constitution, and/or disease for quantitative analysis of interactions between drugs and patients. The domain of pharmacometrics includes the application of techniques that address the interactions between pharmacokinetics, pharmacodynamics, pharmacogenomics, and disease progression with a focus on populations and variability in the exposure-response relationship.

The goal of the Sheiner-Beal Pharmacometrics Award is to recognize outstanding achievements at the forefront of research or leadership in pharmacometrics and/or application of pharmacometric concepts and techniques to enhance research, development, regulatory evaluation, and/or utilization of therapeutic products.

Eligibility 
The candidate must be an investigator or leader who is actively advancing the scientific discipline of pharmacometrics and/or its impact on research, development, regulatory evaluation, or utilization of therapeutic products, and is capable of delivering an engaging and comprehensive lecture on pharmacometrics. The award is intended to recognize clinical pharmacologists, clinician scientists, computational scientists, statisticians, and others in academia, industry, government agencies, or consulting whose work falls within the scope of the definition of pharmacometrics.

Prize and Presentation
The Sheiner-Beal Pharmacometrics Award will be presented annually at the ASCPT Annual Meeting. The recipient will present a lecture summarizing the works that form the basis of the award. In addition, the recipient will receive a $1,500 prize and a plaque. Travel expenses, hotel expenses, and meeting registration will be reimbursed by the Society. 

The Henry W. Elliott Distinguished Service Award was established in 1979 to recognize an ASCPT member who has gone above and beyond the call of duty in service to the organization. 

The goal of the Henry W. Elliott Distinguished Service Award is to acknowledge outstanding efforts on behalf of the organization by an individual member and in doing so, encourage other ASCPT members to contribute their time and talent to the Society. 

Eligibility 
A nominee must be a member of ASCPT. Past Board members who have been off of the Board for at least one year at the time of nomination are eligible to be nominated. The essential criterion is documented evidence of excellent service to the organization. One or two outstanding acts of service or a long record of many acts of service may justify the award. The recipient should have a record of continuous service to the Society, including one or many major accomplishments. 

Prize and Presentation 
The Henry W. Elliott Distinguished Service Award is presented at the ASCPT Annual Meeting. The recipient will receive a plaque and a $1,000 prize. Travel expenses, hotel expenses, and meeting registration will be reimbursed by the Society. 

The William B. Abrams Award in Geriatric Clinical Pharmacology was established with support from the Merck Company Foundation in 1996 to honor an investigator in geriatric clinical pharmacology for outstanding contributions to the field. 

Dr. Abrams, a Past President of ASCPT, had a long and illustrious career in the pharmaceutical industry, mostly at the Merck Research Laboratories. Among his many accomplishments in geriatric clinical pharmacology, he was the founding Co-Editor of the Merck Manual of Geriatrics, created the Scientific Section on Geriatric Clinical Pharmacology of ASCPT, and developed and funded post-doctoral training programs in geriatric clinical pharmacology. 

Dr. Abrams' objective in establishing this award was to encourage more young scientists to enter the field of geriatric clinical pharmacology by recognizing accomplishments in the field at the Society's Annual Meeting. 

This award is funded on behalf of Dr. Abrams through the generosity of The Merck Company Foundation.

Eligibility 
A nominee must be an investigator in geriatrics who is actively involved in high-quality teaching and research in geriatric clinical pharmacology. 
 
Prize and Presentation 
The William B. Abrams Award in Geriatric Clinical Pharmacology is presented at the ASCPT Annual Meeting. The recipient will receive a plaque and a $1,000 prize. Travel expenses, hotel expenses, and meeting registration will be reimbursed by the Society.

Malle Jurima-Romet, PhD, was the Senior Director, Drug Development at Celerion. With over 25 years of biomedical and pharmaceutical research experience, Dr. Jurima-Romet was a devoted scientist and outstanding leader in her field. Because of Dr. Jurima-Romet’s thoughtful guidance and leadership she had an unmistakable impact on drug development, her staff and colleagues thrived, and the organizations she contributed her skills to, including the American Society for Clinical Pharmacology and Therapeutics, where she served on the Program Committee and on the Board of Directors, benefited. Along with her devotion to clinical pharmacology, Dr. Jurima-Romet was passionate about art, most notably as a painter and as a master at Ikebana, the art of Japanese flower arranging. The combination of science and art made Dr. Jurima-Romet a unique and talented scientist whose leadership and achievements will have a lasting impact on clinical pharmacology.

The Malle Jurima-Romet Mid-Career Leadership Award will honor the legacy of  Dr. Jurima-Romet by recognizing exceptional leadership and outstanding contributions to clinical pharmacology by a mid-career clinical pharmacologist and encourage continued leadership and future impactful scientific contributions to clinical pharmacology.

Eligibility
The nominees should be recognized leaders in their field who have reached their mid-career, defined as at least 10 years post-specialty training. The nominee must be able to provide evidence of exceptional and ongoing leadership, excellent scientific achievements in their particular area of practice and a commitment to the future of clinical pharmacology and translational medicine. The nominee may practice clinical pharmacology in an academic, industrial, government, or consulting setting.

Criteria
The nominees must provide evidence of four or more of the following:

  1. Mentorship – The nominee actively serves as a role model or mentor who shows dedication to the development and advancement of future leaders in the field of clinical pharmacology and therapeutics.
  2. Team Building  – The nominee demonstrates a commitment to team building, values and respects the contributions of team members, has the ability to engage all parties and allows all involved to share ownership in achievements.
  3. Professional Growth – The nominee shows a commitment to professional development and encourages professional development in others.
  4. Leadership Roles – The nominee holds positions that effectively promote and advance the field of clinical pharmacology and therapeutics and is recognized as a leader among peers.
  5. Service to the Society – The nominee demonstrates exemplary volunteer contributions to the American Society for Clinical Pharmacology and Therapeutics.  
  6. Initiative – The nominee demonstrates initiative and goes above and beyond the standard measures to achieve a successful outcome.  
Prize and Presentation
The Malle Jurima-Romet Mid-Career Leadership Award will be presented during the ASCPT Annual Meeting. The recipient will receive a $1,000.00 honorarium and a token of recognition.

 

The Darrell Abernethy Early Stage Investigator Award is intended to foster the growth of early career scientists. This award honors the memory of Darrell Abernethy, MD, PhD, who was a leader in clinical pharmacology and a devoted advocate for discipline of clinical pharmacology. During his career, Darrell was a successful mentor to hundreds of mentees and it was his wish that any award be dedicated to helping young faculty succeed in the area of investigative clinical pharmacology.

Requirements:

  • The applicant must have completed a graduate degree at the time of grant award and be within 3 years of appointment as an instructor or assistant professor in either a division/department with a clinical pharmacology/translational medicine focus or have completed a fellowship focused in clinical pharmacology/translational medicine.
  • The applicant must be a US/Canadian citizen or permanent resident of the US.
  • The applicant must be a member of ASCPT at the time of the application and receipt of the award.
  • Applicants must show evidence of heading up an independent research laboratory or of being an early stage investigator with promise for a successful career.
  • Applicants must indicate percentage of time to be committed to research during the award period, with expectation being 60%.
  • At the conclusion of the grant period, a final report is required highlighting the project’s progress and summarizing the usage of the funds.
  • Applicants agree to provide ASCPT permission to publish names, likeness, and a summary of the funded award in Clinical Pharmacology & Therapeutics or other Society journals and publications.
Additional considerations:
  • Recipient will be provided with an ASCPT member mentor (scientific or career mentor).
  • Recipient is encouraged to submit their research for presentation at the ASCPT Annual Meeting as either an oral or poster presentation.
Prize and Presentation
The Darrell Abernethy Early Stage Investigator Award will receive a grant for a one-year period, October 1, 2019 – September 30, 2020, for the total amount of $10,000.

The recipient will be formally recognized at the ASCPT Annual Meeting and will be provided with complimentary registration to attend the award presentation.

 

The ASCPT Mentor Award was established in 2011 by the ASCPT Education Committee. A mentor is one of the most influential figures in the life of a student/trainee in the field of pharmacology and translational medicine. This award will recognize an ASCPT member who serves in a mentoring role, making a significant impact in the career of his or her mentee, and contributes to the retention of young members.

The candidate for this award must be an ASCPT member who has participated in the ASCPT Mentoring Program. 

Prize and Presentation
The ASCPT Mentor Award recipient will be recognized during the Opening Session at the Annual Meeting, will receive a plaque, and will be acknowledged in the Annual Meeting Program.

The William B. Abrams Lecture is a joint educational initiative of ASCPT and the FDA. The lecture series, supported in part by The Merck Company Foundation, was established in 1999 to honor William B. Abrams, MD, an ASCPT president from 1975 to 1976.

Among his many accomplishments, Dr. Abrams worked at the FDA as the first special government employee to establish the Center for Drug Evaluation and Research Staff College and develop its curriculum. He also had a distinguished career in the pharmaceutical industry as a longtime employee of Merck Research Laboratories.

For more than 10 years, ASCPT and the FDA have invited experts from academia, industry, and government to discuss advances in clinical pharmacology and drug development. These scientists have excelled in their specialty areas and are some of the most highly esteemed clinical pharmacologists in the field. Their presentations convey novel information and perspectives on fundamental aspects of clinical pharmacology. Previous lectures have included speakers from the Mayo Clinic, University of California, Children's Mercy Hospitals and Clinics, and the National Institutes of Health.

*At the discretion of the Scientific Awards Selection Task Force, and with majority support of its members, an award nominee may be re-purposed to a different award.

  • Instructions for Nominators
  • Nomination FAQ
  • Letter of Recommendation Guidelines

*All nominators must be ASCPT members.

  1. Before nominating a candidate for an award, please visit the corresponding webpages below to familiarize yourself with the specific award criteria and the history of award recipients.  Please note that Past Board members who have been off of the Board for at least one year at the time of nomination are eligible for awards.

  2. Pull together your nomination package. The nomination package for all awards except the Darrell Abernethy Early Stage Investigator Award should include:
    1. One nominator’s or self-assessment (max length 5 pages) summarizing important aspects of the nominee’s CV and a comprehensive evaluation of all aspects of the candidate’s outstanding attributes that qualify the person for the specific award. The assessment is to be written by the lead nominator.
    2. 1-3 letters of recommendation (max length 2 pages each) preferably including at least one from outside the nominee’s institution. The lead nominator is responsible for coordinating and collating these letters into one package.
    3. The candidate’s CV (max length 25 pages) highlighting in particular the scientific accomplishments and qualifications for the award; or in the case of the Henry W. Elliott Distinguished Service Award, the candidate’s extraordinary commitment of time and talent to ASCPT. 
    *The nomination package should not include copies of publications or other copyrighted or protected intellectual property

    **If nominating or applying for the Darrell Abernethy Early Stage Investigator Award, please see additional instructions here and submit the documents listed below:
    • A cover letter briefly summarizing the applicant's qualifications and a description of ongoing/proposed research. Please suggest the names of three (3) potential scientific or career mentors.
    • Applicant's curriculum vitae.
    • No more than 5 pages that describe the Project. Suggested formal and page lengths are Summary/Abstract (1/2 - 1 page), Specific Aims (1 page), and the Research Strategy (limit 2 pages) and additionally, a section on the protection of human subjects (no limit) if appropriate.
    • Three letters of recommendation with one letter from the candidates Division Chief or Department Chair or Dean demonstrating support of the candidate and for the application.
    • Copy of one of the applicant's publications that he/she consider his/her best work.

  3. To submit an award nomination, please login to the ASCPT website and click on the Award Submission link included on your Dashboard. Only ASCPT members are able to submit award nominations.
Who can nominate a person for an award?
To submit an award nomination, please login to the ASCPT website and click on the Award Submission link included on your Dashboard. Only ASCPT members are able to submit award nominations.  Past Board members who have been off of the Board for at least one year at the time of nomination are eligible for awards.

What should my nomination packet include?
The nomination package should include:
  1. Nominator’s assessment (max length 5 pages) summarizing important aspects of the nominee’s CV and a comprehensive evaluation of all aspects of the candidate’s outstanding attributes that qualify them for the specific award. 
  2. 1-3 letters of recommendation (max length 2 pages each) preferably including at least one from outside the nominee’s institution; 
  3. The candidate’s CV (max length 25 pages) highlighting in particular the scientific accomplishments and qualifications for the award; or in the case of the Henry W. Elliott Distinguished Service Award, the candidate’s extraordinary commitment of time and talent to ASCPT. 
*The nomination package should not include copies of publications or other copyrighted or protected intellectual property. 

**If nominating or applying for the Darrell Abernethy Early Stage Investigator Award, please see additional instructions here and submit the documents listed below:
  • A cover letter briefly summarizing the applicant's qualifications and a description of ongoing/proposed research. Please suggest the names of three (3) potential scientific or career mentors.
  • Applicant's curriculum vitae.
  • No more than 5 pages that describe the Project. Suggested formal and page lengths are Summary/Abstract (1/2 - 1 page), Specific Aims (1 page), and the Research Strategy (limit 2 pages) and additionally, a section on the protection of human subjects (no limit) if appropriate.
  • Three letters of recommendation with one letter from the candidates Division Chief or Department Chair or Dean demonstrating support of the candidate and for the application.
  • Copy of one of the applicant's publications that he/she consider his/her best work.
Which sectors of clinical pharmacology practice are appropriate for nomination?
The nominee’s sector of clinical pharmacology practice is comprehensive; the nominee can include an international academic (e.g., basic or clinical research), industrial (e.g., big/small PHARMA, BIOTECH, CROs, consulting), or regulatory scientist, with various types of accomplishments that signify the candidate’s outstanding science. 

What types of accomplishments would qualify a person for an award?
Publications in highly impactful scientific journals are key examples that point to substantial accomplishment; but publications are neither mandatory nor the exclusive evidence of such accomplishment. It is the responsibility of the nominator to provide adequate detail about documented evidence and public information and aspects of the candidate’s specific accomplishments that unequivocally warrant the recognition of the award. This may include the description of materials such as (but not limited to):
  • Publications
  • Patents
  • Inventions
  • Methodologies
  • New drug applications
  • Individual influence on drug discovery
  • Drug development and regulatory decisions,
  • Process changes
  • Other products of clinical pharmacology rendering scientific excellence
The letter(s) of recommendation should:
  • Supplement and confirm the lead nominator’s assessment. 
  • Convey the impact of the candidate’s scientific contribution from the perspective of the author(s) of the letter. 
  • Document the recognition of a candidate’s outstanding science (or service for the Henry W. Elliott Distinguished Service Award) by including supporting materials that are derived from sources inside and outside the candidate’s own institution.
*Letters of recommendation may be written by a single individual (particularly when they have a unique informed perspective of the candidate’s accomplishments) or by two or more co-authors providing a composite perspective of the candidate’s accomplishments to which each of the co-authors testifies by their signature on the letter. 

Questions

If you have any questions about any of the awards or nomination procedures, please email meetings@ascpt.org or (703) 836-6981, ext. 108. 
Photo Gallery
Recent News
Contact Us